NCT05369377 Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia Status NOT_YET_RECRUITING Phase PHASE2
NCT05369364 The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia Status NOT_YET_RECRUITING Phase PHASE2
NCT05356858 An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients Status TERMINATED Phase PHASE2
NCT05326308 Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma Status RECRUITING Phase N/A
NCT05214391 A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia Status RECRUITING Phase PHASE2
NCT05202782 Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05200312 A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma Status UNKNOWN Phase PHASE2
NCT05199909 Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia Status RECRUITING Phase PHASE2
NCT05117814 Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma Status UNKNOWN Phase NA
NCT05100862 A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05068440 Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib Status COMPLETED Phase PHASE2
NCT04899570 Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma Status UNKNOWN Phase PHASE2
NCT04850495 Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04840602 Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Status RECRUITING Phase PHASE2
NCT04835870 Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Status UNKNOWN Phase PHASE2